A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

Brief description of study

This is a first-in-human modular Phase 1, open-label, multi-center study to evaluate the safety and tolerability and identify a recommended phase 2 dose (RP2D) of AZD9592 alone and with a specific combination treatment, in EGFR and cMET expressing tumors, initially NSCLC EGFR mut (L858R/ex19del) and wild type, as well as HNSCC. The study will also evaluate the preliminary efficacy, PK, PD and immunogenicity of AZD9592.


Clinical Study Identifier: s22-00831
ClinicalTrials.gov Identifier: NCT05647122
Principal Investigator: Sally Lau.
Other Investigators: Marta Wioleta Wronska, Elaine Shum, David Mendoza, Nitish Mehta, Vamsidhar Velcheti, Shun Yu, Danny Perlaza, Laura Palazzolo, Jessica Wang, Jonathan B Kahn, Joshua K Sabari, Keriann M Scavone, Marissa Rybstein, Natalia Cherkassky, Nina Beri, Avital Benson, Jagdeep Raince, Elka R Travis, Salman Rafi Punekar, Carol M Lee, Jeffrey G Schneider, Jennifer Chuy, Paul E. Oberstein, Samantha VanMaanen, Daniel J Becker, Kristen Spencer, James Newman, Gabrielle Fridman, Melissa L Martinez, Michael Shusterman, Rafael Winograd, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.